F-spore activation
Jun 16, 2006

Biosensor Platform


BCR Corporation Presents An Innovative Breakthrough Biosensor Platform at National Institutes of Health "Life Sciences Showcase"

Category: General
Posted by: boris123

Jamestown, Rhode Island, June 16, 2006 – BCR Diagnostics, a pioneer in spore-based biosensor technology, announced today that it has been selected by the National Institutes of Health to take part in the final stage of its Commercialization Assistance Program (NIH-CAP) called the Life Sciences Showcase. The opportunity will provide BCR the chance to present its latest technologic breakthrough to a group of business development executives, venture capitalists and industry leaders, and hone its commercialization strategy in an effort to bring its products to market. “NIH-CAP has been an invaluable experience,” said Boris Rotman, CSO at BCR. “We’ve gained insight into our business plan, received feedback from key experts and explored business opportunities for the future. Our goal is to find a strategic partner to help us through the FDA approval process and I’m optimistic about the outcome.” At the Showcase, BCR will discuss its novel engineering process for creating synthetic phenotypes in living Bacillus spores. Specifically, BCR will discuss fluorogenic spores (F-spores™) designed to perform as self-reporters of viability. “An important commercial application of F-spores™ is rapid (less than 60 minutes) sterility testing,” said Rotman. “Conventional tests using normal spores require two to four days so a real-time alternative is crucial to ensuring safety in the healthcare, pharmaceutical and food and beverage industries.” The NIH-CAP Life Sciences Showcase will be held on June 29 at the San Jose Convention Center in Silicon Valley, California.

# # #

About BCR Diagnostics: Founded by Boris Rotman (emeritus professor of Brown University Medical School), BCR is a privately held Rhode Island corporation dedicated to developing novel biosensor platforms for detecting extremely low levels of bacteria in less than 30 minutes. Life-saving applications for BCR's products include clinical diagnostics, biological warfare defense, testing platelets intended for transfusion, screening food and beverages, and environmental monitoring. For more information, visit www.bcrbiotech.com.

News
Apr 18, 2017
Category: General
Posted by: boris123

 

Chandler, Arizona, April 18, 2017

        Taking sterility testing to higher levels, BCR Corp. offers a remarkably simple and rapid Biological Indicator (BI) containing spores of heat-resistant bacteria.

        The BCR-30-min BI™ is the first rapid BI that perfectly matches CDC’s definition of an ideal monitoring system.

 

 

Oct 29, 2014
Category: General
Posted by: boris123

Simple Technology Could Reduce Cost of Fluorescence-based Instrumentation by More than Five-fold


Jan 14, 2011
Category: General
Posted by: boris123

BCR Diagnostics relocates to Chandler, Arizona

Nov 8, 2010
Category: General
Posted by: boris123

BCR Diagnostics awarded $204,630 grant under Qualifying Therapeutic Discovery Project (QTDP) program

Jun 16, 2006
Category: General
Posted by: boris123

BCR Corporation Presents An Innovative Breakthrough Biosensor Platform at National Institutes of Health "Life Sciences Showcase"